This is an old revision of this page, as edited by Beetstra (talk | contribs) at 13:09, 18 January 2011 (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:09, 18 January 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Other names | R089439 |
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| PubChem CID | |
| ChemSpider | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H16Cl2N2O2 |
| Molar mass | 351.227 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Loviride (also called Loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials Loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.
External links
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |